Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00926614 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

A Phase 4 study of Hepatitis C, sponsored by Brooke Army Medical Center.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT00926614 is a Phase 4 study of Hepatitis C that has completed, run by Brooke Army Medical Center. The registered enrollment target is 20 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00926614, a Phase 4 study of Hepatitis C, has completed, sponsored by Brooke Army Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The aim of the study will be to determine if an insulin sensitizing thiazolidinedione plus a lipid lowering agent (statin) improves sustained virologic response rates in patients who have previously not responded or relapsed on standard pegylated interferon and ribavirin therapy.

Conditions Studied

Hepatitis C

Interventions

  • DRUG pioglitazone (Actos)
  • DRUG atorvastatin (Lipitor)

Study Locations (1)

Texas

  • Brooke Army Medical Center - San Antonio

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-09
Est. Completion 2011-12
Phase Phase 4

Sponsor

Brooke Army Medical Center

54 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00926614

The ClinicalTrials.gov registry entry for NCT00926614 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The listed sponsor is Brooke Army Medical Center, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which pioglitazone (Actos) is the first listed.

NCT00926614 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00926614 about?

NCT00926614 is a clinical study titled "Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba". The aim of the study will be to determine if an insulin sensitizing thiazolidinedione plus a lipid lowering agent (statin) improves sustained virologic response rates in patients who have previously not responded or relapsed on standard pegylated interferon and ribavirin therapy.

What is the current status of trial NCT00926614?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2008-09. Estimated completion is 2011-12.

What conditions does trial NCT00926614 study?

This clinical trial studies the following conditions: Hepatitis C.

What interventions are being tested in trial NCT00926614?

The interventions under investigation include: pioglitazone (Actos) (DRUG), atorvastatin (Lipitor) (DRUG).

Who is sponsoring clinical trial NCT00926614?

This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00926614 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.